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The effect of immunosuppression may mask the
typical signs of infective keratitis, potentially
resulting in a devastating delay in diagnosis.
Case report
Awoman with type 2 diabetes, rheumatoid arthritis
and secondary Sjo ¨gren’s syndrome developed
severe corneal ulceration (keratitis) on two separate
occasions three years apart while taking systemic
immunosuppression for her rheumatoid arthritis.
Her ocular history included Sjo ¨gren’s syndrome-
related dry eyes for which she used non-preserved
ocular lubricants, together with recurrent episodes
of marginal keratitis treated successfully with
topical steroids and prophylactic antibiotics on an
outpatient basis. The early management strategies
foreach of thesevere clinical episodes are presented
and the clinical outcomes for both eyes, discussed.
Clinical episode 1: left eye
The patient originally presented acutely aged 44
years, to a dedicated ophthalmology accident
and emergency department with pain and
blurred vision in her left eye. She was found to
have an area of crescenteric-shaped corneal thin-
ning associated with an epithelial defect, peri-
pheral corneal vascularization and cellular
inﬁltration of the normally clear cornea, consistent
with a diagnosis of presumed autoimmune per-
ipheral ulcerative keratitis. Despite emergency
admission and initial treatment with intensive
one-hourly non-preserved topical Dexamethasone
0.1% day and night, together with a single infu-
sion of i.v. methylprednisolone and maintenance
of her existing DMARD regime of Methotrexate
12.5 mg weekly, the corneal inﬁltration and ulcera-
tion rapidly progressed. After revising the diagno-
sis to rheumatoid peripheral ulcerative keratitis
(corneal melt) with secondary microbial keratitis,
appropriate microbiological sampling (corneal
‘scrape’) with direct inoculation onto agar plates
was undertaken and broad spectrum topical anti-
biotics (intensive non-preserved topical Gentami-
cin 0.3% and Cefuroxime 5% [each 1 hourly])
were initiated. Unfortunately, a fulminant and
refractory infected peripheral ulcerative keratitis
ensued accompanied by severe destruction of the
left eye, corneal perforation and endophthalmitis
(Figure 1a). The microbial agent was conﬁrmed
as Streptococcus pneumoniae which was isolated
from both corneal sampling and a subsequent vitr-
eous (intraocular) biopsy. The eye was eventually
eviscerated (removed) just 10 days after her orig-
inal presentation, and the orbit rehabilitated with
an orbital implant and cosmetic ocular prosthesis.
The patient was subsequently cared for in a ter-
tiary inﬂammatory eye diseases clinic for manage-
ment of her Sjo ¨gren’s syndrome dry eye problems
with non-preserved topical lubricants (Carboxy-
methylcellulose 1%, Sodium hyaluronate 0.18%
each 6x/day), and the regional rheumatology
service for her rheumatoid arthritis.
Clinical episode 2: right eye
Threeyears later, the patient presented acutelyagain
totheinﬂammatoryeyediseaseservice(nowaged47
years), three months after an uneventful routine eye
outpatient clinic attendance with a few days history
of pain, redness and blurred vision in her right and
only eye, occurring within 4 weeks of her second
infusion of the ﬁrst cycle of Rituximab for her rheu-
matoid arthritis. Her visual acuity was reduced to
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16/18 and she was found to have an identical periph-
eralinfero-temporalcrescentericareaofkeratitiswith
minimal associated corneal inﬁltration, but signiﬁ-
cantcornealmeltwithupto70%thinning(Figures1b
and 1c). Shewas afebrile and systemically well. With
a working diagnosis of a microbial keratitis second-
ary to an autoimmune peripheral ulcerative keratitis
precipitated by severe Sjo ¨gren’s syndrome dry eye
and immunosuppression, she underwent corneal
‘scrapes’ for microbiological analysis and rapid
diagnostics. The patient was admitted and com-
menced on intensive broad-spectrum topical anti-
biotics (Oﬂoxacin 0.3%, Cefuroxime 5% each 1
hourly) in addition to oral Ciproﬂoxacin 750 mg b.
d.(administeredasprophylaxisagainstsystemicdis-
semination of infection), Doxycycline (a metallo-
matrix proteinase inhibitor) and ascorbic acid (col-
lagenase inhibitor). Haematological screening con-
ﬁrmed a normal total white blood cell count (5.0 x
10
9/L) with borderline low lymphocytes (1.12×
10
9/L [normal:1–4.5 ×10
9/L]) and normal neutro-
phils (3.11×10
9/L [normal:1.7–7.5×10
9/L]). All
other investigations including her vasculitic
markers, glucose, urinalysis, chest radiography and
b l o o dc u l t u r e sw e r en o r m a l .D u et ot h eh i g hr i s ko f
perforation and previous left evisceration, the
patient was given a single pulse of i.-
v. Methylprednisolone 1g, 24 hours after initiation
of topical bactericidal antibiotics to sterilize.
Microscopy demonstrated Gram-negative cocci,
conﬁrmed after 48 h culture as Neisseria meningitides
with likely sensitivities to penicillin. Her treatment
was adjusted accordingly (replacement of Cefurox-
ime with non-preserved Penicillin 5% every hour);
and due to the notiﬁable nature of the disease,
advice from the Public Health Consultant was to
trace and prophylactically treat all nearest contacts
w i t has i n g l ed o s eo fo r a lC i p r o ﬂ o x a c i n5 0 0 m g .
Despite her vulnerability to disseminated meningo-
coccal disease, the patient remained afebrile and
systemically well. Within one week, there was sig-
niﬁcant improvement in the keratitis, permitting a
gradualreductionoftopicalantibioticsandwithdra-
w a lo fo r a lC i p r o ﬂ o x a c i na f t e rs e v e nd a y s .N o n -
preserved topical Prednisolone 0.5% qds was intro-
duced cautiously at day 12 to reduce damage by the
local inﬂammatory response. She was discharged
home 13 days after admission. All topical treatment
was withdrawn over the ensuing three months
other than her existing non-preserved tear-ﬁlm sub-
stitutes. Over the subsequent 12 months there was
no recurrence of ocular inﬂammation with her
visual acuity recovering to 6/12 (Figure 2). No
further infusions of Rituximab were given in view
of the ocular complication and that her rheumatoid
arthritis did not respond optimally to Rituximab.
Discussion
This case highlights a number of diagnostic and
management challenges. Local and systemic
Figure 1
(A) Colour photograph of the left eye prior to
evisceration (removal of the contents of the eye).
Note the severe conjunctival congestion and
scleritis, opaque cornea, large corneal perforation
(arrowed) and hypopyon (pus cells inside the
anterior chamberof the eye) indicating the classic
signs of a severe, fulminant and destructive
infection, which emerged following treatment for
an autoimmune peripheral ulcerative keratitis
without excluding a secondary corneal infection;
(B) similarly, the right eye at presentation did not
demonstrate the cardinal features of inﬂam-
mation showing a discrete crescenteric area of
corneal opacity between 3 o’clock and 6 o’clock
(arrow); and (C) excavated (thinned) area
suggestive of corneal ‘melt’ (arrow)
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2immunosuppression masks the typical signs of
overt corneal infection such as frank corneal
abscess, epithelial defect and hypopyon. It is,
therefore, important to have a high index of suspi-
cion of an infective component in immunosup-
pressed patients presenting with a breakdown of
the corneal epithelium. In this mildly lymphopae-
nic patient, the exclusion of a systemic source of
sepsis was aggressively pursued when she pre-
sented with problems with her second eye. The
major dilemma pending microbiological conﬁr-
mation of infection was whether the keratitis
was: (1) pure autoimmune peripheral ulcerative
keratitis; (2) peripheral ulcerative keratitis with a
secondary infection; or (3) infective keratitis
alone. Incorrect diagnosis and treatment can
result in potentially blinding complications as
exempliﬁed by the loss of the patient’s ﬁrst eye:
this was treated as a peripheral ulcerative keratitis
alone with topical and intravenous steroids
without suspicion of a concomitant infection.
The consequence was devastating ocular tissue
destruction and eventual complete loss of the
eye (Figure 1a).
We recommend that in all cases of acute periph-
eral ulcerative keratitis, appropriate ocular micro-
biological sampling (by the receiving
ophthalmologist) is undertaken before commen-
cing 24 h of intensive topical antibiotics day and
night to initiate microbial sterilization of the
cornea, followed by the introduction of 1–3
pulses of i.v. Methylprednisolone to treat an
autoimmune component,
1 supplemented by
lubrication to facilitate epithelial migration
across the ocular surface and healing. Systemic
Doxycycline and ascorbic acid should also be
administered to reduce the risk of perforation
and promote corneal stromal-matrix remodelling
by inhibiting metallo-matrix proteases, collagen-
ases, and scavenging free radicals.
Methotrextate is a ‘broad-spectrum’ steroid
sparing disease modifying agent which is a folic
acid analogue that interferes with thymidine syn-
thesis and, therefore, with DNA synthesis and cell
division. It has little effect in resting cells but has
pronounced effect on rapidly proliferating cells,
affecting both B and T cells, and can inhibit both
humoral and cellular responses. By contrast,
Rituximab is a monoclonal antibody directed
against the CD20 molecule expressed on B-cells,
and is now an established therapy in rheumatoid
arthritis following at least two failed DMARDS
including at least one anti-TNF agent.
2 Its action
is thought to include suppression of antigen pres-
entation and antibody/cytokine production. B-cell
depletion is rapid and may persist for up to 6
months.
3-4 Adverse effects include infusion reac-
tions and an increased risk of serious infections.
In two large randomized control trials, pneumo-
nia, bronchitis, epiglottitis, gastroenteritis, pyelo-
nephritis, cat-bite infection, inﬂuenza, fever of
unknown aetiology, and de-novo hepatitis B were
reported.
3,4 Although these studies did not ident-
ify an increased risk of opportunistic infections,
there have been subsequent reports of a number
of unusual infections most notably Pneumocystis
pneumonia.
5
To our knowledge this is the second report of
meningococcal opportunistic infection occurring
after the use of Rituximab.
6 N. meningitidis is a
Gram-negative diplococcus, which is a familiar
cause of bacterial meningitis and overwhelming
sepsis (meningococcaemia) with a mortality of
up to 30%. N. meningitidis colonises the nasophar-
ynx in 8–25% of the normal population
7 and is
spread byairborne droplets resulting in a subclini-
cal infection with only a minority of individuals
developing metastatic spread including meningi-
tis, sepsis or occasionally endogenous
endophthalmitis.
8 The risk of the disease is
greater in children, those with complement
deﬁciencies and in the immunosuppressed
7 (the
previous report in the context of Rituximab
Figure 2
Colour photographs of the right eye at 12 months
after appropriate staged introduction of treat-
ment for corneal infection followed by treatment
for autoimmune peripheral ulcerative keratitis
administered in quick succession. Note the cres-
centeric area of opacity has resolved, leaving only
a shallow area of thinning with minimal scarring
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3involved a splenectomised individual
6). In the
case discussed here the use of Rituximab will
have rendered the patient more susceptible to
meningococcal infection due to iatrogenic host
B-cell depletion. Meningococcal conjunctivitis
(including ophthalmia neonatorum) is uncommon
in both infants and adults,
9,10 and may present as
primary or secondary to systemic disease.
11 The
isolation of N. meningitidis as the causative agent
for keratitis is rare, but can complicate meningo-
coccal conjunctivitis in 15% patients.
9 The poten-
tial for sight-threatening and life-threatening
intraocular or systemic invasion necessitates
prompt and aggressive treatment with systemic
antibiotics.
10 In the UK, both of these sequelae
require notiﬁcation under the Public Health
(Infectious Diseases) Regulations 1988.
These episodes of peripheral ulcerative keratitis
with superimposed infection sequentially affect-
ing both eyes of the same patient, demonstrate
the challenges of recognizing microbial keratitis
in the immunosuppressed and underlines the
need for all specialists to remain vigilant to the
possibility of atypical infections, particularly in
the context of the newer biological therapies.
This is also the ﬁrst reported case of an opportu-
nistic meningococcal keratitis associated with
Rituximab use.
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